Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Merck Serono ditches cladribine, leaving MS franchise exposed

This article was originally published in Scrip

Executive Summary

Merck Serono has finally given up on cladribine, its oral candidate for relapsing remitting multiple sclerosis. It has withdrawn the product from the approval process in the US and will cease to pursue approval everywhere else. It will also withdraw the product from sale in Russia and Australia, where it is marketed as Movectro.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register